IBM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IBM is not a clear buy right now for a Beginner long-term investor with $50,000-$100,000 who does not want to wait for a better entry. The business fundamentals are solid, but the stock’s current technical setup is still weak and the analyst community is mixed. I would not call this a strong buy today; the better call is to hold off or wait for improvement above resistance.
IBM is trading pre-market at 232.82, slightly above the prior current price reference of 230.98 and up 0.80% pre-market, which is constructive. However, the broader trend is still bearish: MACD histogram is -1.427 and below zero, the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, and RSI_6 at 39.37 shows weak-to-neutral momentum rather than a confirmed rebound. Key levels matter here: pivot is 239.975, resistance is 254.021, and support is 225.929. The stock is still below the pivot, so the trend has not fully turned bullish yet. The short-term pattern data suggests upside potential over the next week and month, but the current chart is not a clean entry for a patient long-term buyer who wants immediate conviction.
Recent news is supportive overall. HSBC upgraded IBM to Hold from Reduce, citing improved margins, productivity savings, and stronger expectations for software and quantum computing. IBM also launched Bob, a productivity tool aimed at enterprise development efficiency, which supports the software growth narrative. The company continues to show enterprise AI momentum, including its partnership with Arm. The Q1 financial report was strong, with revenue up 9.46% YoY, net income up 15.26% YoY, EPS up 14.29% YoY, and gross margin improving to 56.22%.
Despite the positive business news, analyst sentiment is still mixed rather than strongly bullish. Several firms cut price targets after Q1, with comments that software organic growth was light in places and that the market may have expected more. Morgan Stanley kept an Equal Weight view, and BMO said it still struggles to justify IBM’s premium software multiple at the current organic growth profile. Trading trends from hedge funds and insiders are neutral, and there is no recent congress trading data. Technically, IBM remains below key resistance and the moving average structure is still bearish.
Latest quarter: 2026/Q1. IBM posted revenue of $15.917B, up 9.46% YoY, net income of $1.216B, up 15.26% YoY, EPS of $1.28, up 14.29% YoY, and gross margin of 56.22%, up 1.79% YoY. This is a healthy quarter showing both growth and margin expansion, which supports the long-term story. The financial trend is positive, especially for a large-cap mature company.
Analyst direction has improved slightly but remains mixed. HSBC upgraded IBM to Hold from Reduce and raised its target to $231, while DZ Bank upgraded to Buy with a $295 target. On the more cautious side, Morgan Stanley kept Equal Weight with a $225 target, and BMO kept Market Perform with a $270 target. Wedbush, Jefferies, RBC, and Oppenheimer remain constructive overall but lowered targets due to multiple compression and near-term softness. Wall Street pros see clear strengths in software, AI adoption, and productivity savings, but the cons are slower organic growth in some areas and a valuation that is not yet fully justified by the current growth profile. No recent politician or influencer buying/selling was reported, and hedge funds/insiders are neutral.
